NKG2D Natural Killer Cell Receptor-A Short Description and Potential Clinical Applications

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2021 Jul 2

PMID 34200375

Citations 28

Authors

Jagoda Siemaszko

Aleksandra Marzec-Przyszlak

Katarzyna Bogunia-Kubik

Affiliations

Soon will be listed here.

Abstract

Natural Killer (NK) cells are natural cytotoxic, effector cells of the innate immune system. They can recognize transformed or infected cells. NK cells are armed with a set of activating and inhibitory receptors which are able to bind to their ligands on target cells. The right balance between expression and activation of those receptors is fundamental for the proper functionality of NK cells. One of the best known activating receptors is NKG2D, a member of the CD94/NKG2 family. Due to a specific NKG2D binding with its eight different ligands, which are overexpressed in transformed, infected and stressed cells, NK cells are able to recognize and attack their targets. The NKG2D receptor has an enormous significance in various, autoimmune diseases, viral and bacterial infections as well as for transplantation outcomes and complications. This review focuses on the NKG2D receptor, the mechanism of its action, clinical relevance of its gene polymorphisms and a potential application in various clinical settings.

Citing Articles

Natural Killer Cells in Graves' Disease: Increased Frequency but Impaired Degranulation Ability Compared to Healthy Controls.

Gallo D, Piantanida E, Bombelli R, Lepanto S, Bruno A, Gallazzi M Int J Mol Sci. 2025; 26(3).

PMID: 39940745 PMC: 11816991. DOI: 10.3390/ijms26030977.

Antitumor effects of natural killer cells derived from gene-engineered human-induced pluripotent stem cells on hepatocellular carcinoma.

Nakamura M, Tanaka Y, Hakoda K, Ohira M, Kobayashi T, Kurachi K Cancer Immunol Immunother. 2025; 74(3):99.

PMID: 39904787 PMC: 11794780. DOI: 10.1007/s00262-025-03940-5.

Cell type-specific upregulation of NKG2D ligand MICA in response to APTO253.

Alkhayer R, Ponath V, Pogge von Strandmann E Ann Transl Med. 2025; 12(6):113.

PMID: 39817244 PMC: 11729809. DOI: 10.21037/atm-24-20.

and gene polymorphisms influence graft survival, and response to therapy in kidney transplantation.

Littera R, Mocci S, Argiolas D, Littarru L, Lai S, Melis M Front Immunol. 2024; 15:1440887.

PMID: 39575256 PMC: 11578996. DOI: 10.3389/fimmu.2024.1440887.

Natural killer cell engagers: From bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy.

Zhu A, Bai Y, Nan Y, Ju D Clin Transl Med. 2024; 14(11):e70046.

PMID: 39472273 PMC: 11521791. DOI: 10.1002/ctm2.70046.

References

Ge X, Li C, Yang J, Wang G . Aberrantly decreased levels of NKG2D expression in children with kawasaki disease. Scand J Immunol. 2013; 77(5):389-97. DOI: 10.1111/sji.12022. View

Perricone R, Di Muzio G, Perricone C, Giacomelli R, De Nardo D, Fontana L . High levels of peripheral blood NK cells in women suffering from recurrent spontaneous abortion are reverted from high-dose intravenous immunoglobulins. Am J Reprod Immunol. 2006; 55(3):232-9. DOI: 10.1111/j.1600-0897.2005.00356.x. View

Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K . Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000; 356(9244):1795-9. DOI: 10.1016/S0140-6736(00)03231-1. View

Hu B, Bao G, Zhang Y, Lin D, Wu Y, Wu D . Donor NK Cells and IL-15 promoted engraftment in nonmyeloablative allogeneic bone marrow transplantation. J Immunol. 2012; 189(4):1661-70. DOI: 10.4049/jimmunol.1103199. View

Lee J, Lee K, Kim D, Heo D . Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004; 172(12):7335-40. DOI: 10.4049/jimmunol.172.12.7335. View

Zhu L, Aly M, Wang H, Karakizlis H, Weimer R, Morath C . Increased natural killer cell subsets with inhibitory cytokines and inhibitory surface receptors in patients with recurrent miscarriage and decreased or normal subsets in kidney transplant recipients late post-transplant. Clin Exp Immunol. 2018; 193(2):241-254. PMC: 6046488. DOI: 10.1111/cei.13142. View

Hayashi T, Imai K, Morishita Y, Hayashi I, Kusunoki Y, Nakachi K . Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance. Cancer Res. 2006; 66(1):563-70. DOI: 10.1158/0008-5472.CAN-05-2776. View

Abel A, Yang C, Thakar M, Malarkannan S . Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018; 9:1869. PMC: 6099181. DOI: 10.3389/fimmu.2018.01869. View

Koike J, Wakao H, Ishizuka Y, Sato T, Hamaoki M, Seino K . Bone marrow allograft rejection mediated by a novel murine NK receptor, NKG2I. J Exp Med. 2004; 199(1):137-44. PMC: 1887729. DOI: 10.1084/jem.20030851. View

10.

Ogasawara K, Benjamin J, Takaki R, Phillips J, Lanier L . Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nat Immunol. 2005; 6(9):938-45. PMC: 1351289. DOI: 10.1038/ni1236. View

11.

Zhang Y, Huang C, Lian R, Xu J, Fu Y, Zeng Y . The low cytotoxic activity of peripheral blood NK cells may relate to unexplained recurrent miscarriage. Am J Reprod Immunol. 2021; 85(6):e13388. DOI: 10.1111/aji.13388. View

12.

Fabritius C, Ritschl P, Resch T, Roth M, Ebner S, Gunther J . Deletion of the activating NK cell receptor NKG2D accelerates rejection of cardiac allografts. Am J Transplant. 2017; 17(12):3199-3209. PMC: 5694344. DOI: 10.1111/ajt.14467. View

13.

Pu X, Hildebrandt M, Lu C, Roth J, Stewart D, Zhao Y . Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy. Clin Pharmacol Ther. 2014; 96(3):360-369. PMC: 4141040. DOI: 10.1038/clpt.2014.89. View

14.

Karimi M, Bryson J, Richman L, Fesnak A, Leichner T, Satake A . NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT. Blood. 2015; 125(23):3655-63. PMC: 4458804. DOI: 10.1182/blood-2015-02-629006. View

15.

Mirjacic Martinovic K, Lj Babovic N, Dzodic R, Jurisic V, Tanic N, Konjevic G . Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients. Melanoma Res. 2014; 24(4):295-304. DOI: 10.1097/CMR.0000000000000072. View

16.

Liu X, Sun M, Yu S, Liu K, Li X, Shi H . Potential therapeutic strategy for gastric cancer peritoneal metastasis by NKG2D ligands-specific T cells. Onco Targets Ther. 2015; 8:3095-104. PMC: 4622417. DOI: 10.2147/OTT.S91122. View

17.

Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen X . Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res. 2009; 15(16):5208-15. DOI: 10.1158/1078-0432.CCR-09-0886. View

18.

Baragano Raneros A, Martin-Palanco V, Fernandez A, Rodriguez R, Fraga M, Lopez-Larrea C . Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia. Genes Immun. 2014; 16(1):71-82. DOI: 10.1038/gene.2014.58. View

19.

Egerup P, Lindschou J, Gluud C, Christiansen O . The Effects of Intravenous Immunoglobulins in Women with Recurrent Miscarriages: A Systematic Review of Randomised Trials with Meta-Analyses and Trial Sequential Analyses Including Individual Patient Data. PLoS One. 2015; 10(10):e0141588. PMC: 4627734. DOI: 10.1371/journal.pone.0141588. View

20.

Fechtenbaum M, Desoutter J, Delvallez G, Brochot E, Guillaume N, Goeb V . MICA and NKG2D variants as risk factors in spondyloarthritis: a case-control study. Genes Immun. 2018; 20(7):599-605. PMC: 6768283. DOI: 10.1038/s41435-018-0044-x. View